Royalty Pharma posts Q3 earnings, raises full‑year guidance and deploys $1.6 bn in new royalties
Royalty Pharma reported third‑quarter 2026 revenue of $690.1 million, a 13.3% year‑over‑year increase, and adjusted earnings of $1.21 per share, beating the $1.18 consensus. Portfolio receipts rose 9% to $890 million and the company announced $1.6 billion of capital deployment, including two new royalty acquisitions. Management raised its full‑year guidance for the second straight quarter and returned about $590 million to shareholders via dividends and buybacks.
Why it matters
The raised guidance signals higher expected full‑year revenue, which could support the stock’s recent rally. The $1.6 bn capital deployment and new royalty deals expand the asset base, while the $590 m return to shareholders improves cash yield for investors.
Key facts
- 1Q3 2026 revenue was $690.1 million, up 13.3% from the prior-year quarter. tradingview.com
- 2Adjusted earnings were $1.21 per share, beating the $1.18 consensus. finance.yahoo.com
- 3Portfolio receipts grew 9% year‑over‑year to $890 million. investing.com
- 4Royalty Pharma deployed $1.6 billion of capital in 2026, including two royalty acquisitions. finance.yahoo.com
- 5The company returned approximately $590 million to shareholders through dividends and share repurchases in the first nine months. finance.yahoo.com
- 6Cash on hand was $514 million and debt was $8.8 billion as of September 30, 2026. seekingalpha.com
Summary written by AlphAI AI Desk from 9 of 9 sources. Not investment advice. Figures are as stated by the linked sources.